Altura Medical has grabbed $6 million in new venture equity financing, according to a regulatory filing.
The FDA has lost another chief information officer. After leading an IT reboot at the agency for less than two years, Eric Perakslis left his position effective March 5 and an interim CIO will serve until a permanent replacement is found, FDA spokeswoman Sandy Walsh said in an email to FierceBiotech IT .
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Johnson & Johnson and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract manufacturer. But it also figured out a process by which it could have it manufactured at one plant and finished at another.
Despite all the advances in medical devices for Type 1 diabetes, nothing resembling an artifical pancreas has made its way to the market stateside, but companies like Medtronic, Johnson & Johnson and Tandem are working to push the technology forward.
While the FDA has yet to give its final sign-off to this creative work-around, it has permitted the Johnson & Johnson subsidiary to release a lot at a time, the latest last week.
Already sky-high expectations for the experimental cancer drug ibrutinib from J&J and Pharmacyclics managed to arc even higher this morning after the collaborators spread word that the program had just won its third "breakthrough drug" title from the FDA.
Animas, Johnson & Johnson's insulin pump unit, is recalling its 2020 devices, warning that a malfunction may lead to unintended insulin delivery and put patients at risk.
A federal appeals court threw out a radiologist's $482 million patent infringement victory against Johnson & Johnson, validating the Cypher drug-eluting stents once produced by its Cordis subsidiary. One man's victory against a giant corporation lasted about two years.
The venture arms for Johnson & Johnson and Pfizer have helped spearhead an $18 million investment round for Canada's Aquinox Pharmaceuticals as the biotech plots the next big step in a mid-stage program for its lead anti-inflammatory drug.